Most Read Articles
Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

Dr. Victor Lee, 30 Sep 2020
A 75-year-old gentleman presented to our clinic in February 2019, following a routine check-up showing an elevation of carcinoembryonic antigen (CEA) to 2,900 ng/mL (normal range, ≤3 ng/mL). The patient was an ex-smoker who quit approximately 10 years ago, having smoked 10–20 cigarettes a day for 40 years prior to quitting. He had diabetes mellitus (DM) and hypertension and was receiving appropriate medication for both. 

Rationale and clinical evidence for the use of tumour-treating fields in the treatment of glioblastoma and other cancers

24 Apr 2020
Tumour-treating fields (TTFields) are a non-invasive anticancer treatment modality that utilizes low-intensity, intermediate-frequency (100–300 kHz), alternating electric fields delivered through transducer arrays placed around the tumour region to inhibit tumour cell division.  

These TTFields affect various charged and polar molecules within rapidly dividing cancer cells. Through interfering with the structure of microtubules and the movement of organelles during cell division, TTFields cause abnormal mitosis, leading to cell death, blocking of cell division or the formation of lethal chromosomal aberrations. 

Sponsored as a service to the medical profession by Zailab Optune.Editorial development by MIMS MedComms.The opinions expressed in this publication are not necessarily those of the editor, publisher or sponsor.Any liability or obligation for loss or damage howsoever arising is hereby disclaimed.© 2020 MIMS (Hong Kong) Limited. All rights reserved.No part of this publication may be reproduced by any process in any language without the written permission of the publisher
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

Dr. Victor Lee, 30 Sep 2020
A 75-year-old gentleman presented to our clinic in February 2019, following a routine check-up showing an elevation of carcinoembryonic antigen (CEA) to 2,900 ng/mL (normal range, ≤3 ng/mL). The patient was an ex-smoker who quit approximately 10 years ago, having smoked 10–20 cigarettes a day for 40 years prior to quitting. He had diabetes mellitus (DM) and hypertension and was receiving appropriate medication for both.